Standout Papers

Concurrent once-daily versus twice-daily chemoradiotherapy in patients with limited-stage small-cell l... 2017 2026 2020 2023 335
  1. Concurrent once-daily versus twice-daily chemoradiotherapy in patients with limited-stage small-cell lung cancer (CONVERT): an open-label, phase 3, randomised, superiority trial (2017)
    Corinne Faivre‐Finn, M. Snee et al. The Lancet Oncology

Citation Impact

1 by Nobel laureates 15 from Science/Nature 75 standout
Sub-graph 1 of 21

Citing Papers

Colorectal cancer
2024 Standout
[177Lu]Lu-DOTA-TATE plus long-acting octreotide versus high‑dose long-acting octreotide for the treatment of newly diagnosed, advanced grade 2–3, well-differentiated, gastroenteropancreatic neuroendocrine tumours (NETTER-2): an open-label, randomised, phase 3 study
2024 Standout
2 intermediate papers

Works of N. Mohammed being referenced

Concurrent once-daily versus twice-daily chemoradiotherapy in patients with limited-stage small-cell lung cancer (CONVERT): an open-label, phase 3, randomised, superiority trial
2017 Standout
Improving patient survival with the colorectal cancer multi‐disciplinary team
2008

Author Peers

Author PRM Oncology Molecular Biology Last Decade Papers Cites
N. Mohammed 339 522 306 28 940
James N. Rogers 1 4 5 21 224
Vitruvius 3 70
Mami Nakahara 20 85 87 14 372
Emanuela Manno 4 5 6 485
Beatriz M. Braganca 8 22 346 32 603

All Works

Loading papers...

Rankless by CCL
2026